MYGN Myriad Genetics Inc.

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Management will also participate in two upcoming healthcare conferences

SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m. EST. The company’s quarterly earnings will be released the same day after the market closes.  

During the call, Myriad management will provide a financial overview and business update of the company’s performance for the fourth quarter and full year 2023. Revenue and earnings guidance for 2024 will also be shared.

A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at . To participate in the live conference call via telephone, please . Upon registering, a dial-in number and unique PIN will be provided to join the conference call. Following the conference call, an archived webcast of the call will be available at .

March Investor Conferences

Management will also be participating in the following investor conferences:

  • The 45th Annual Raymond James & Associates Institutional Investors Conference with a presentation from Paul J. Diaz, president and CEO, and Scott Leffler, chief financial officer, on March 4, 2024, at 4:35pm EST.
  • The 44th Annual Cowen Health Care Conference with a fireside chat featuring Sam Raha, chief operating officer, and Ben Wheeler, chief financial officer – operations, on March 5, 2024, at 12:50pm EST.

A live and archived webcast of both presentations can be viewed in the investor relations section of Myriad’s website at  .

About Myriad Genetics 

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .   

Investor Contact

Matt Scalo

(801) 584-3532

Media Contact

Glenn Farrell

(385) 318-3718



EN
21/02/2024

Underlying

MYGNMyriad Genetics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myriad Genetics Inc.

Jonathan Moreland
  • Jonathan Moreland
Free Trial
ABG ASBURY AUTOMOTI...
CSGP COSTAR GROUP IN... ... (+34)

InsiderInsights.com Daily Ratings Report: March 9, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ABG ASBURY AUTOMOTIVE GROUP INC
CSGP COSTAR GROUP INC
XRAY DENTSPLY SIRONA INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
SFM SPROUTS FARMERS MARKETS INC.
NWBI NORTHWEST BANCSHARES INC.
MYGN MYRIAD GENETICS INC.
FFIN FIRST FINANCIAL BANKSHARES INC
COTY COTY INC. CLASS A
NXRT NEXPOINT RESIDENTIAL TRUST INC.
WHF WHITEFIELD
ORN ORION GROUP HOLDINGS
THO THOR INDUSTRIES INC.
TTEC TELETECH HOLDINGS
HOG INC.
GO HARLEY-DAVIDSON INC.
ALT GROCERY OUTLET HOLDING
TSLX ALTIMMUNE INC
VERX SIXTH STREET SPECIALTY LENDING
ADV INC.
TKNO VERTEX
AIRS INC.
QSI ADVANTAGE SOLUTIONS INC (A)
FRST ALPHA TEKNOVA
TCBX INC.
EBC AIRSCULPT TECHNOLOGIES INC
NBBK QUANTUM-SI INC
MXF PRIMIS FINANCIAL CORP
LYEL THIRD COAST BANCSHARES INC
EASTERN BANKSHARES INC
NB BANCORP INC.
THE MEXICO FUND
INC.
LYELL IMMUNOPHARMA INC.
03/09/26 March 9, 2026 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Myriad Commercially Launches Precise MRD with Select Community Oncolog...

Myriad Commercially Launches Precise MRD with Select Community Oncologists Launch Represents Significant Step to Broader Commercialization SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the ™ (molecular residual disease) test with a select number of oncology practices for patients with breast cancer. “The limited release of Precise MRD represents an important milestone in cancer care for patients and the clinicians who guide their care. By detecting ctDNA at extremely low...

March 2, 2026 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
VRSK Verisk Analytic...
VNO Vornado Realty ... ... (+59)

InsiderInsights Weekly Report: February 28, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

VRSK VERISK ANALYTICS INC
VNO VORNADO REALTY TRUST
TYL TYLER TECHNOLOGIES INC.
TBI TRUEBLUE INC.
REXR REXFORD INDUSTRIAL REALTY INC.
PODD INSULET CORPORATION
NEU NEWMARKET CORPORATION
MYGN MYRIAD GENETICS INC.
MSCI MSCI INC. CLASS A
LXRX LEXICON PHARMACEUTICALS INC.
HUM HUMANA INC.
HMN HORACE MANN EDUCATORS CORPORATION
HCI HCI GROUP INC.
FAF FIRST AMERICAN FINANCIAL CORPORATION
CEVA CEVA INC.
CAR AVIS BUDGET GROUP INC.
OFIX ORTHOFIX INTERNATIONAL N.V.
WY WEYERHAEUSER COMPANY
TZOO TRAVELZOO
FIVN FIVE9 INC.
PRU PRUDENTIAL PLC
SAH SONIC AUTOMOTIVE INC. CLASS A
SXC SUNCOKE ENERGY INC.
WINA WINMARK CORP.
ITIC INVESTORS TITLE CO.
GGT THE GABELLI MULTIMEDIA TRUST
CNDT CONDUENT INC.
HLNE HAMILTON LANE INCORPORATED CLASS A
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
SSTI SHOTSPOTTER
KKR KKR & CO. INC.
BOTJ BANK OF THE JAMES FINANCIAL GROUP INC.
UBER UBER TECHNOLOGIES INC.
AVTR AVANTOR
VERX INC.
BIGC VERTEX
NBR INC.
SLQT BIGCOMMERCE HOLDINGS
DLHC NABORS INDUSTRIES LTD.
ABCL SELECTQUOTE
CVRX INC.
ELF DALEIGH HOLDINGS CORP
FLYW ABCELLERA BIOLOGICS
BLCO CVRX
FSCO INC.
CADL E.L.F. BEAUTY
CVI INC.
TLSI FLYWIRE CORP
ASST BAUSCH + LOMB CORP
EKSO FS CREDIT OPPORTUNITIES CORP.
LNZA CANDEL THERAPEUTICS
INC.
CVR ENERGY
INC.
TRISALUS LIFE SCIENCES INC
ASSET ENTITIES INC.
EKSO BIONICS HOLDINGS INC.
LANZATECH GLOBAL INC
03/02/26 March 2, 2026 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
REXR Rexford Industr...
MYGN Myriad Genetics... ... (+9)

InsiderInsights.com Daily Ratings Report: February 27, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

REXR REXFORD INDUSTRIAL REALTY INC.
MYGN MYRIAD GENETICS INC.
HTGC HERCULES CAPITAL INC.
HMN HORACE MANN EDUCATORS CORPORATION
WINA WINMARK CORP.
AXR AMREP
ABCL ABCELLERA BIOLOGICS
WRB W.R. BERKLEY CORPORATION
FSCO FS CREDIT OPPORTUNITIES CORP.
02/28/26 February 28, 2026 1 EN
 PRESS RELEASE
Free
MYGN Myriad Genetics...

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact ...

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting its TM (Molecular Residual Disease) Test, ® Prostate Cancer Prognostic Test and ® Hereditary Cancer Tests. These data highlight Myriad’s expanding role across the cancer care continuum, including ultra-sensitive molecular residual disease detection, prognostic stratification,...

February 24, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch